Literature DB >> 12594449

Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure.

John R Teerlink1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12594449     DOI： 10.1067/mhj.2003.151

Source DB:  PubMed          Journal:  Am Heart J        ISSN： 0002-8703            Impact factor:   4.749


× No keyword cloud information.
  16 in total

Review 1.  Nesiritide for acute decompensated heart failure: does the benefit justify the risk?

Authors:  Jonathan Sackner-Bernstein; Keith D Aaronson
Journal:  Curr Cardiol Rep       Date:  2007-05       Impact factor: 2.931

2.  Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries.

Authors:  Stephen J Greene; Ami N Shah; Javed Butler; Andrew P Ambrosy; Stefan D Anker; Ovidiu Chioncel; Sean P Collins; Wilfried Dinh; Preston M Dunnmon; Gregg C Fonarow; Carolyn S P Lam; Robert J Mentz; Burkert Pieske; Lothar Roessig; Giuseppe M C Rosano; Naoki Sato; Muthiah Vaduganathan; Mihai Gheorghiade
Journal:  Am Heart J       Date:  2014-05-24       Impact factor: 4.749

3.  Effects of tolvaptan on dyspnoea relief from the EVEREST trials.

Authors:  Peter S Pang; Marvin A Konstam; Holly B Krasa; Karl Swedberg; Faiez Zannad; John E A Blair; Christopher Zimmer; John R Teerlink; Aldo P Maggioni; John C Burnett; Liliana Grinfeld; John Ouyang; James E Udelson; Mihai Gheorghiade
Journal:  Eur Heart J       Date:  2009-06-27       Impact factor: 29.983

4.  Relation of dyspnea severity on admission for acute heart failure with outcomes and costs.

Authors:  Robert J Mentz; Xiaojuan Mi; Puza P Sharma; Laura G Qualls; Adam D DeVore; Katherine Waltman Johnson; Gregg C Fonarow; Lesley H Curtis; Adrian F Hernandez
Journal:  Am J Cardiol       Date:  2014-10-15       Impact factor: 2.778

5.  Evaluation of a provocative dyspnea severity score in acute heart failure.

Authors:  Omar F AbouEzzeddine; Anuradha Lala; Prateeti P Khazanie; Ravi Shah; Jennifer E Ho; Horng H Chen; Peter S Pang; Steven E McNulty; Kevin J Anstrom; Adrian F Hernandez; Margaret M Redfield
Journal:  Am Heart J       Date:  2015-10-20       Impact factor: 4.749

6.  Validation of a three-factor measurement model of dyspnea in hospitalized adults with heart failure.

Authors:  Mark B Parshall; Adam C Carle; Unchalee Ice; Robert Taylor; Joyce Powers
Journal:  Heart Lung       Date:  2011-07-27       Impact factor: 2.210

Review 7.  Learning from recent trials and shaping the future of acute heart failure trials.

Authors:  Robert J Mentz; Gary Michael Felker; Tariq Ahmad; William Frank Peacock; Bertram Pitt; Mona Fiuzat; Aldo P Maggioni; Mihai Gheorghiade; Yuki Ando; Stuart J Pocock; Faiez Zannad; Christopher M O'Connor
Journal:  Am Heart J       Date:  2013-09-13       Impact factor: 4.749

8.  Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity in acute heart failure (MEASURE-AHF).

Authors:  Larry A Allen; Marco Metra; Olga Milo-Cotter; Gerasimos Filippatos; Leonardo H Reisin; Daniel R Bensimhon; Edoardo G Gronda; Paolo Colombo; G Michael Felker; Livio Dei Cas; Dimitrios T Kremastinos; Christopher M O'Connor; Gadi Cotter; Beth A Davison; Howard C Dittrich; Eric J Velazquez
Journal:  J Card Fail       Date:  2008-08-15       Impact factor: 5.712

9.  Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study.

Authors:  Marco Metra; John R Teerlink; G Michael Felker; Barry H Greenberg; Gerasimos Filippatos; Piotr Ponikowski; Sam L Teichman; Elaine Unemori; Adriaan A Voors; Beth Davison Weatherley; Gad Cotter
Journal:  Eur J Heart Fail       Date:  2010-08-22       Impact factor: 15.534

Review 10.  Levosimendan: a review of its use in the management of acute decompensated heart failure.

Authors:  Carmen A Innes; Antona J Wagstaff
Journal:  Drugs       Date:  2003       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.